エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number: 001-41661
JIN MEDICAL INTERNATIONAL LTD.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
In March 2024, DNTW Toronto LLP (“DNTW”), the former registered public accounting firm of Jin Medical International Ltd. (the “Company”), issued a letter through its legal advisor to the Company, indicating that there was an unresolved disagreement between DNTW and the Company regarding the scope of audit procedures during the period from September 23, 2023 to February 25, 2024 when DNTW served as the auditor of the Company. DNTW advised that the unresolved disagreement mainly focused on the scope of audit procedures necessary for DNTW to complete its work and form an opinion on the Company’s September 30, 2023 financial statements. This disagreement remained unresolved to DNTW’s satisfaction as of the date hereof, which led to a dispute between the parties resulting in an impairment of DNTW’s independence under applicable professional standards and DNTW's resignation as the Company’s auditors. Additionally, there was a disagreement regarding the effective date of DNTW’s resignation, which DNTW believes was February 25, 2024 while the Company believes such effective date was February 26, 2024 instead.
The Company believes that DNTW could not reach an agreement with the Company on the time required for completion of certain audit procedures, which resulted in the disagreement on the scope of the audit procedures. The Company’s board of directors, audit committee and management discussed the disagreement internally and attempted to discuss the subject matter of this disagreement with DNTW but could not reach a consensus. As such, the disagreement remained unresolved to the date of DNTW’s resignation.
On March 1, 2024, the Company has authorized DNTW to fully respond to inquiries from the successor accountant regarding the subject matter of this disagreement.
EXHIBIT INDEX
| Exhibit No. | Description | |
| 16.1 | Letter from DNTW Toronto LLP , dated April 12, 2024 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| JIN MEDICAL INTERNATIONAL LTD. | ||
| Date: April 12, 2024 | By: | /s/ Erqi Wang |
| Erqi Wang | ||
| Chief Executive Officer | ||
| By: | /s/ Ziqiang Wang | |
| Ziqiang Wang | ||
| Chief Financial Officer |
Exhibit 16.1
 |
 |
April 12, 2024
U.S. Securities and Exchange Commission
Office of the Chief Accountant
100 F Street, N.W.
Washington, DC 20549
Re: Jin Medical Technologies Ltd.
Dear Sirs:
We have read the statements made by Jin Medical Technologies Ltd. (the “Company”) in its Form 6-K filed with the Securities and Exchange Commission on April 12, 2024, which we take as a supplement to its Form 6-K filed on March 1, 2024. DNTW Toronto LLP (“DNTW”) was not provided an opportunity to review and comment on the Form 6-K filed on March 1, 2024 prior to its filing.
With respect to the Form 6-K filed on April 12, 2024:
We agree with the statements the first paragraph of the Form 6-K that DNTW, a PCAOB-registered accounting firm, is the former auditor of Jin Medical and that DNTW issued a letter through its legal counsel to the Company. By way of clarification, on March 13, 2024 DNTW’s legal counsel wrote to the Company’s legal counsel confirming that the March 1, 2024 Form 6-K was inaccurate and incomplete in several respects. Specifically, the March 13, 2024 letter confirmed that the date of DNTW’s resignation was February 25, 2024; and also confirmed that as of the date of DNTW’s resignation there was an unresolved disagreement between DNTW and the Company regarding the scope of audit procedures to be performed by DNTW before being in a position to issue an audit report on the Company’s September 30, 2023 financial statements. The March 13, 2024 letter, which requested on behalf of DNTW that Jin Medical promptly amend its March 1, 2024 Form 6-K to correct these issues, was followed by a letter from DNTW’s legal counsel dated March 23, 2024, setting forth additional details on for the areas of disagreement and reiterating DNTW’s request that Jin Medical promptly amend its March 1, 2024 Form 6-K to correct these issues.
By way of further clarification, prior to DNTW’s resignation as the Company’s auditors, DNTW had outlined to the Company’s leadership the areas where DNTW concluded that additional information, and the opportunity to perform additional audit procedures relating to that information, were required in order for DNTW to complete its work and issue an audit report. The Company’s position was that such information and procedures were unnecessary and that litigation would be instituted against DNTW if it did not immediately issue its audit report. DNTW concluded that the threat of litigation resulted in an impairment of its independence as the Company’s auditors and thereafter resigned as the Company’s auditors on February 25, 2024.
We neither agree nor disagree with statements in the second paragraph of the Form 6-K, reflecting internal discussions of the Company. We agree with the statement that there were unresolved disagreements with the Company at the time of DNTW’s resignation.
|
|
We agree with the statements in the third paragraph of the Form 6-K.
Very truly yours,
DNTW Toronto LLP
Chartered Professional
Accountants
Licensed Public Accountants
Cc: Erqi Wang (CEO) and Yanru Guo (Audit Committee Chair), Jin Medical Technolgies Ltd via email